RECRUITING

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Talk to us

Conditions

Multiple MyelomaIberdomideCC-220LenalidomideMMNDMMMaintenanceAutologous stem cell transplantASCTm

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).

Official Title

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)

Quick Facts

Study Start:2023-06-22
Study Completion:2036-01-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05827016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
855-907-3286
Clinical.Trials@bms.com
First line of email MUST contain NCT # and Site #.
CONTACT

Principal Investigator

Bristol-Myers Squibb
STUDY_DIRECTOR
Bristol-Myers Squibb

Study Locations (Sites)

Rocky Mountain Cancer Centers
Aurora, Colorado, 80012-5405
United States
Mayo Clinic Florida
Jacksonville, Florida, 32224
United States
Tampa General Hospital
Tampa, Florida, 33606
United States
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, 33612-9416
United States
Cleveland Clinic
Weston, Florida, 33331-3609
United States
University Cancer Blood Ctr
Athens, Georgia, 30607-1465
United States
The Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322-1013
United States
Augusta University - Georgia Cancer Center
Augusta, Georgia, 30912
United States
The University of Chicago Medical Center - Duchossois Center for Advanced Medicine
Chicago, Illinois, 60637-1426
United States
University of Kansas Cancer Center - The Richard and Annette Bloch Cancer Care Pavilion
Westwood, Kansas, 66205-2003
United States
Maryland Oncology Hematology, PA- Clinton
Clinton, Maryland, 20735-4230
United States
UMass Memorial Medical Center
Worcester, Massachusetts, 01655
United States
University of Michigan - Rogel Cancer Center
Ann Arbor, Michigan, 48109-5000
United States
Henry Ford Health System - The Henry Ford Cancer Institute (HFCI) - Detroit
Detroit, Michigan, 48202-2610
United States
Cancer & Hematology Centers of Western Michigan (CHCWM)
Grand Rapids, Michigan, 49503
United States
Mayo Clinic Cancer Center (MCCC) - Rochester
Rochester, Minnesota, 55905
United States
Hattiesburg Clinic - Hematology & Oncology
Hattiesburg, Mississippi, 39401
United States
Midwest Oncology Associates - Kansas City
Kansas City, Missouri, 64132
United States
Morristown Medical Center
Morristown, New Jersey, 07960
United States
Perlmutter Cancer Center at NYU Langone Hematology Oncology Associates-Mineola
Mineola, New York, 11501
United States
NYU Langone Health
New York, New York, 10016-6402
United States
Columbia University Medical Center - Herbert Irving Pavilion Location
New York, New York, 10032-3729
United States
Clinical Research Alliance
Westbury, New York, 11590
United States
Novant Health Cancer Institute - Elizabeth
Charlotte, North Carolina, 28803-2493
United States
Duke University Hospital
Durham, North Carolina, 27705-3976
United States
Novant Health Cancer Institute Hematology - Forsyth
Winston-Salem, North Carolina, 27103
United States
Oncology Hematology Care, Inc. - Cincinnati - Galbraith Rd
Cincinnati, Ohio, 45236-2725
United States
Cleveland Clinic - Fairview Hospital - Cancer Center (Moll Cancer Center)
Cleveland, Ohio, 44111
United States
Cleveland Clinic
Cleveland, Ohio, 44195
United States
Cleveland Clinic - Hillcrest Hospital - Hillcrest Cancer Center
Mayfield Heights, Ohio, 44124
United States
Toledo Clinic Cancer Centers
Toledo, Ohio, 43623
United States
Wooster Milltown Specialty and Surgery Center
Wooster, Ohio, 44691
United States
Willamette Valley Cancer Institute
Eugene, Oregon, 97401
United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107
United States
Local Institution - 0011
Philadelphia, Pennsylvania, 19111-2433
United States
University of Pittsburgh - Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232
United States
West Cancer Center
Germantown, Tennessee, 38138-1762
United States
Tennessee Oncology
Nashville, Tennessee, 37203-1625
United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246
United States
UT Southwestern-Harold C. Simmons Cancer Center
Dallas, Texas, 75390-0001
United States
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030-4000
United States

Collaborators and Investigators

Sponsor: Bristol-Myers Squibb

  • Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-06-22
Study Completion Date2036-01-01

Study Record Updates

Study Start Date2023-06-22
Study Completion Date2036-01-01

Terms related to this study

Keywords Provided by Researchers

  • Multiple Myeloma
  • Iberdomide
  • CC-220
  • Lenalidomide
  • MM
  • NDMM
  • Maintenance
  • Autologous stem cell transplant
  • ASCTm

Additional Relevant MeSH Terms

  • Multiple Myeloma